Mario Otto, MD, PhD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
UW Health Clinics
UW School of Medicine and Public Health
|Department of Pediatrics|
Professional Certifications and Education
St. Jude Children's Research Hospital, Memphis, TN
Children's University Hospital, Tuebingen, Germany
Akron Children's Hospital, Akron, OH
Children's University Hospital, Tuebingen, Germany
University of Tuebingen School of Medicine, Germany, 1995
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Programs & Conditions
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Adrenocortical carcinoma
- Aplastic Anemia
- Atypical Teratoid/Rhabdoid tumor
- Bleeding Disorders
- Brain Stem Glioma
- Chronic Myeloid Leukemia
- Congenital Hemolytic Anemias
- Cyclic Neutropenia
- Diamond-Blackfan Syndrome
- Endocrine Tumors
- Ewing Sarcoma
- Fanconi's Anemia
- Germ Cell Tumors
- Hemophagocytic Lymphohistiocytosis
- Hemophilia A
- Hemophilia B
- Hereditary Spherocytosis
- Hodgkin's Disease
- Immune Thrombocytopenc Purpura
- Juvenile Myelomonocytic Leukemia
- Kostmann Syndrome
- Langerhans' Cell Histiocytosis
- Myelodysplastic Syndromes
- Neurocutaneous Syndrome
- Non-Hodgkin Lymphomas
- Optic Glioma
- Paroxysmal Nocturnal Hemoglobinuria
- Pediatric Cancer
- Pediatric Sickle Cell Disease
- Shwachman-Diamond Syndrome
- Sturge-Weber Syndrome
- Thalassemia Syndromes
- Thyroid Tumors
- Tuberous Sclerosis
- Vascular malformations
- Von Willebrand Disease
- VonHippel-Lindau Disease
- Wilms Tumor
Dr. Otto is pursuing novel, alternative approaches to treat childhood cancer. His research includes areas such as adoptive immunotherapies, nano-oncology and stem cell graft design for the transplant setting.
Jiao P Otto M Geng Q Li C Li F Butch ER Snyder SE Zhou H Yan B .
Enhancing both CT imaging and natural killer cell-mediated cancer cell killing by a GD2-targeting nanoconstruct. J Mater Chem B Mater Biol Med. 2016 Jan 20;4(3):513-520
[PubMed ID: 27087966]
Marino R Baiu DC Bhattacharya S Titz B Hebron E Menapace BD Singhal S Eickhoff JC Asimakopoulos F Weichert JP Otto M .
Tumor-selective anti-cancer effects of the synthetic alkyl phosphocholine analog CLR1404 in neuroblastoma. Am J Cancer Res. 2015;5(11):3422-35
[PubMed ID: 26807322]
Baiu DC Artz NS McElreath MR Menapace BD Hernando D Reeder SB Grüttner C Otto M .
High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles. Nanomedicine (Lond). 2015 Sep 30;
[PubMed ID: 26420448]
McDowell KA Hank JA DeSantes KB Capitini CM Otto M Sondel PM .
NK cell-based immunotherapies in Pediatric Oncology. J Pediatr Hematol Oncol. 2015 Mar;37(2):79-93
[PubMed ID: 25590232]
Xu Y Baiu DC Sherwood JA McElreath MR Qin Y Lackey KH Otto M Bao Y .
Linker-free conjugation and specific cell targeting of antibody functionalized iron-oxide nanoparticles. J Mater Chem B Mater Biol Med. 2014 Oct 7;2(37):6198-6206
[PubMed ID: 26660881]
Navid F Sondel PM Barfield R Shulkin BL Kaufman RA Allay JA Gan J Hutson P Seo S Kim K Goldberg J Hank JA Billups CA Wu J Furman WL McGregor LM Otto M Gillies SD Handgretinger R Santana VM .
Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol. 2014 May 10;32(14):1445-52
[PubMed ID: 24711551]
Capitini CM Otto M DeSantes KB Sondel PM .
Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncol. 2014;10(9):1659-78
[PubMed ID: 25145434]
Baiu DC Brazel CS Bao Y Otto M .
Interactions of iron oxide nanoparticles with the immune system: challenges and opportunities for their use in nano-oncology. Curr Pharm Des. 2013;19(37):6606-21
[PubMed ID: 23621531]
Otto M Shulkin BL Kundu M Sandlund JT Snyder SE Metzger ML .
Histiocyte-rich xanthomatous pseudotumor mimicking relapse on positron emission tomography imaging in an adolescent with primary mediastinal diffuse large B-cell lymphoma. J Pediatr Hematol Oncol. 2012 Apr;34(3):232-5
[PubMed ID: 22082744]
Jiao P Zhou H Otto M Mu Q Li L Su G Zhang Y Butch ER Snyder SE Jiang G Yan B .
Leading neuroblastoma cells to die by multiple premeditated attacks from a multifunctionalized nanoconstruct. J Am Chem Soc. 2011 Sep 7;133(35):13918-21
[PubMed ID: 21827210]
Sorkin LS Otto M Baldwin WM 3rd Vail E Gillies SD Handgretinger R Barfield RC Ming Yu H Yu AL .
Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain. 2010 Apr;149(1):135-42
[PubMed ID: 20171010]
Barfield R Chen X Otto M Handgretinger R .
Beyond the FACS. Stem Cells. 2007 Nov;25(11):2972
[PubMed ID: 17656640]
Otto M Chen X Martin WJ Leung W Knowles J Holladay M Houston J Handgretinger R Barfield RC .
Selection of stem cells by using antibodies that target different CD34 epitopes yields different patterns of T-cell differentiation. Stem Cells. 2007 Feb;25(2):537-42
[PubMed ID: 17023516]
Otto M Barfield RC Martin WJ Iyengar R Leung W Leimig T Chaleff S Gillies SD Handgretinger R .
Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. Clin Cancer Res. 2005 Dec 1;11(23):8486-91
[PubMed ID: 16322312]
Chen X Barfield R Benaim E Leung W Knowles J Lawrence D Otto M Shurtleff SA Neale GA Behm FG Turner V Handgretinger R .
Prediction of T-cell reconstitution by assessment of T-cell receptor excision circle before allogeneic hematopoietic stem cell transplantation in pediatric patients. Blood. 2005 Jan 15;105(2):886-93
[PubMed ID: 15358630]
Otto M Barfield RC Iyengar R Gatewood J Müller I Holladay MS Houston J Leung W Handgretinger R .
Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation. J Immunother. 2005 Jan-Feb;28(1):73-8
[PubMed ID: 15614047]